Non-Hodgkins Lymphoma
400
23
36
248
Key Insights
Highlights
Success Rate
78% trial completion
Published Results
121 trials with published results (30%)
Research Maturity
248 completed trials (62% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
18.0%
72 terminated out of 400 trials
77.5%
-9.0% vs benchmark
10%
40 trials in Phase 3/4
49%
121 of 248 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 248 completed trials
Clinical Trials (400)
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
Safety and Efficacy of KSVCBD Injection in B-cell Non-Hodgkin's Lymphoma Expressing CD19 and/or BCMA
Biology Studies of Hematologic Cancers
An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene
High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma
Vaccination With Flt3L, Radiation, and Poly-ICLC
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas
EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma
Expanded Access to Venetoclax
Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma